INCOG BioPharma Services, a contract development and manufacturing organization (CDMO) specializing in sterile injectable biopharmaceuticals, is investing in a second 100,000-square-foot building on its campus—increasing its commercial-scale device assembly capacity in support of autoinjectors, pens, wearable injectors, and syringe accessorizing, while also adding new labeling and final packaging capabilities.

The second building will further enable INCOG to offer comprehensive, end-to-end solutions from filling to device assembly and final packaging, streamlining the process and simplifying the supply chain solution for its global biopharma customers. The groundbreaking is set to happen in August.

“We are excited about this new investment and the opportunities it brings,” said Cory Lewis, CEO and Founder of INCOG. “Our customers will have access to a suite of solutions from filling through final packaging. This supply chain integration is essential in accelerating a drug product to commercial launch, and even more important in today’s constrained markets as the need for sterile injectable products is quickly growing to address challenging diseases and improve healthcare outcomes. The hard work and expertise of the team we have built at INCOG has allowed us to accelerate investments and address the immediate needs of the global biopharma industry.”

This expansion will create over 100 additional high-paying jobs, further establishing Fishers, and the state of Indiana, as a global leader in biopharmaceutical innovation and manufacturing.

This project comes on the heels of current work to commission and install a second high-speed syringe and cartridge filling line, along with supporting automated visual inspection equipment. The automated visual inspection and autoinjector assembly capabilities are available now, with the additional syringe filling capacity coming online in Q2 2025. These enhancements further enable INCOG to meet the growing demand for biopharmaceutical solutions that utilize pre-filled syringes and autoinjector delivery mechanisms.